Pharmacokinetic interaction between the CYP3A4 inhibitor ketoconazole and the hormone drospirenone in combination with ethinylestradiol or estradiol.

First published in British Journal of Clinical Pharmacology on 2015 Dec.
Br J Clin Pharmacol. 2015 Dec;80(6):1399-410. doi: 10.1111/bcp.12745. Epub 2015 Oct 28.

Authors: Wiesinger H, Berse M, Klein S, Gschwend S, Höchel J, Zollmann FS, Schütt B

Download full article as Pdf file:

Pdf File

REACHING OUT IS EASY AND FAST – LET’S TALK

Prof. Dr. Thomas Forst

Chairman of the Executive Board

LET’S TALK SCIENCE

+49 621 150 45 – 0

Martin Mulder

Senior Vice President Corporate & Business Development

LET’S TALK BUSINESS

+49 621 150 45 – 0

Pharmacokinetic interaction between the CYP3A4 inhibitor ketoconazole and the hormone drospirenone in combination with ethinylestradiol or estradiol.

Read more

REACHING OUT IS EASY AND FAST – LET’S TALK

You May Also Like

Pharmacokinetics, Safety, and Tolerability of the Novel Tetrameric, High-Relaxivity, Macrocyclic Gadolinium-Based Contrast Agent Gadoquatrane in Healthy Adults

Effect of nivasorexant (ACT-539313), a selective orexin-1-receptor antagonist, on multiple cytochrome P450 probe substrates in vitro and in vivo using a cocktail approach in healthy subjects

CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes